SEC Form 8-K Summary
Business Context and Reporting Period
Vallon Pharmaceuticals, Inc. filed a Form 8-K on February 14, 2022, reporting results for the year ended December 31, 2021, and providing a business update. The request identifies GRI Bio, Inc., but the filing’s registrant is Vallon Pharmaceuticals, Inc. (NASDAQ: VLON).
Financial Results and Key Metrics
The filing states that the company issued a press release announcing its 2021 financial results. The provided filing text does not include the attached Exhibit 99.1 press release or specific figures for revenue, net income or loss, cash flow, margins, debt, cash, or liquidity.
Material Changes Versus the Prior Period
The filing text does not provide a clear comparison with the prior comparable period or quantify any year-over-year changes.
Guidance, Outlook, Risks, and Unusual Items
The company stated that it provided a business update in the press release. Specific guidance, outlook, management commentary, risks, contingencies, and unusual items are not included in the provided text.
The information was furnished under Item 2.02 and was not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other SEC filings.
Investor Verification Checklist
- Obtain and review Exhibit 99.1 for the actual 2021 financial results and business update.
- Verify cash, liquidity runway, operating cash burn, debt, and financing needs.
- Assess revenue, operating expenses, net loss, and year-over-year changes.
- Review any clinical, regulatory, commercial, or corporate developments described in the omitted press release.
- Confirm the applicable issuer, since the supplied request names GRI Bio, Inc. while the filing identifies Vallon Pharmaceuticals, Inc.